BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy

Transcription

1 Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel # Therapeutic Area: Disease Area(s): Specialty/Location: Publication Date: Principal Authors: Product Code: Hematology / Oncology T- Cell Immunotherapy Oncology N. America; Europe May 2014 Kim Grant, Tricia Hanlon, Jeff Berk IMM #

2 Cancer Immunotherapy; Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma is the 38th hematology/oncology Thought Leader Panel published by BOLT International. We conducted in- depth interviews with ten peer recognized experts in the treatment of these three diseases. We asked them to summarize the successes and challenges in establishing immunotherapy as a co- pillar of modern cancer treatment along with chemotherapy and targeted therapy. And while other solid tumors can already be added to the list, the thought leaders focused on these three as they evaluated checkpoint inhibitors (certainly too narrow of a description), tumor infiltrating lymphocytes, biological response modifiers, vaccines and chimeric antigen receptors. This report captures their collective wisdom. Keywords in this report: checkpoint, ipilimumab, Yervoy, MK- 3475, Merck, nivolumab, BMS , Bristol- Myers Squibb, BMS, BRAF, MEK, Pegasys, interferon, aldesleukin, Prometheus, Avastin, bevacizumab, sunitinib, Votrient, pazopanib, GlaxoSmithKline, Inlyta, axitinib, Afinitor, everolimus, Novartis, MPDL3280A, Roche, Genentech, tremelimumab, AstraZeneca, MedImmune, MSB C, EMD Serono, MEDI0680, MEDI4736, BiocerOX, pidilizumab, CT- 011, CureTech, Teva, ANB011, AnaptysBio, OX40, Medimmune, BMS663513, urelumab, 41- BB, CD137, PF , PF- 2566, Pfizer, TRX- 518, GITR, VISTA, B7- H5, Gi24, Dies1, Janssen, ImmuNext, B7- H3, CD276, MGA- 271, Servier, Macrogenics, LAG- 3, lymphocyte- activation gene 3, CD223, BMS , IMP321, IMP701, Immutep, TIM- 3,T cell immunoglobulin and mucin domain 3, Brigham & Women s, IDO, Indoleamine 2, 3- dioxygenase, INCB24360, Incyte, indoximod, NewLink, NLG919, NewLink, KIR, lirilumab, MICA, IPH4102, Innate Pharma, PS, phosphatidyl serine, bavituximab, Peregrine, TIL, tumor Infiltrating lymphocytes, adoptive T- cell transfer, biological response modifiers, IL- 2, Pegasys, Roche, Proleukin, High Dose IL2, Prometheus, IL12, Ad- RTS- hil- 12, Ziopharm, T- cell Vaccines, talimogene laherparepvec, T- VEC, Amgen, AGS- 003, Argos, Tumor Associated Peptide Vaccines, IMA901, Immatics Biotechnologies GmbH, CAR, Carbonic Anhydrase IX CAR, Kite Pharmaceuticals, Anti- VEGFR2 CAR, NIH, melanoma, non- small cell lung cancer, renal cell carcinoma, PD- 1, PD- L1, CD274, B7- H1, PD- L2, CD273, B7- DC, PD- L4, CTLA4, B7.1, CD80, B7.2, CD86, repulsive guidance molecule b, RGMb 2

3 3

4 4

5 5